Article Text
PDF
Statistics from Altmetric.com
- arthritis (rheumatoid)
- osteoarthritis
- peptic ulcer
- cyclo-oxygenase inhibitors
- anti-inflammatory agents (non-steroidal)
QUESTION: In patients with osteoarthritis or rheumatoid arthritis, does the reduction in gastrointestinal (GI) complications seen with coxibs offset their increased cost compared with non-steroidal anti-inflammatory drugs (NSAIDs)?
Design
Cost utility analysis using a decision analytic model from the perspective of a third party payer considering direct medical costs.
Setting
USA.
Patients
A hypothetical cohort of patients 60 years of age with osteoarthritis or rheumatoid arthritis who were not taking aspirin and required NSAID therapy for moderate to severe arthritis pain.
Intervention
Patients who entered the model were treated with a coxib (celecoxib, 200 mg once daily, or rofecoxib, 25 mg once daily) or a non-selective NSAID at the maximum dose approved by the US Food and Drug Administration (naproxen, 500 mg twice daily). The model was designed to test the hypothesis that coxibs are cost effective alternatives to NSAIDs.
Main cost and outcome measures
A decision tree was constructed to represent the coxib and naproxen strategies. Clinical probability estimates …
Supplementary materials
Related BMJ news item
Merck withdraws arthritis drug worldwide
Debashis Singh
BMJ 2004;329:816, doi:10.1136/bmj.329.7470.816-a
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.